Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005227235
Tue, 07.05.2024
Biotest AG
PRESS RELEASE
Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
Product sales increased by 17.7% to Euro 138.0 million
EBIT increased to Euro 52.8 million
Successful completion Fibrinogen study
Dreieich, 07 May 2024. The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 202 [ … ]
Thu, 29.02.2024
Biotest AG
PRESS RELEASE
Biotest achieves EBIT forecast for 2023
Proposal to this year's Annual General Meeting that preference dividend for the 2023 financial year and the subsequent payment of the preference dividend for the 2022 financial year to be distributed to the preference shareholders.
Dreieich, 29 February 2024: According to p [ … ]
Wed, 28.02.2024
Biotest AG
PRESS RELEASE
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
Plasma donation in Germany secures the long-term supply of vital medicines for patients
State-of-the-art plasma service centre opened in Cologne-Mülheim in January
Dreieich, 28 February [ … ]
Wed, 14.02.2024
Biotest AG
PRESS RELEASE
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
Positive results confirm excellent safety profile
Top-line data demonstrate that Fibrinogen concentrate treatment is as effective as standard of care, either cryoprecipitate or fresh frozen plasma, in reducing intraoperative bl [ … ]
Thu, 18.01.2024
Biotest AG
PRESS RELEASE
Biotest AG opens 11th plasma collection centre in Germany
37 plasma collection centres in Europe to secure long term plasma supply
Dreieich, 18 January 2024. Biotest has officially opened the 11th plasma collection centre in Germany in Cologne.
In the ultra-modern centre on Wiener Platz in Cologne-Mülheim, p [ … ]
Tue, 12.12.2023
Biotest AG
PRESS RELEASE
Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)
Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development
Clinical development of trimodulin is conducted in two clinical trials in the therapeutic area of res [ … ]
Tue, 28.11.2023
Biotest AG
PRESS RELEASE
Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation
Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development for treatment of pneumonia
Trimodulin supports and modulates the dysregulated immu [ … ]
Thu, 02.11.2023
Biotest AG
PRESS RELEASE
Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023
Turnover grows by 38.7 % to Euro 500 million
Technology transfer and licensing agreement concluded with Grifols
Two new plasma centres opened
Dreieich, 2 November 2023: In the first nine months of the 2023 financial year, the Biotest Group recorded r [ … ]
Thu, 21.09.2023
Biotest AG
PRESS RELEASE
Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK
New approval enables future sales growth
Important therapeutic option for paediatric and adult patients with congenital and acquired immunodeficiencies as well as for immunomodulation
Manufactured in highly efficient Biotest Next Level produc [ … ]
Tue, 12.09.2023
Biotest AG
PRESS RELEASE
Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin
Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development
Development in a therapeutic area of high unmet medical need
Significant reduction in mortality expected i [ … ]